Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating efficacy of its anti-inflammatory IL1RAP-binding antibody CAN10 in an additional model of systemic sclerosis. CAN10 alleviated disease manifestations in this model, which is one of the most commonly used models of the disease. These findings will be presented in an oral presentation at the annual rheumatology conference ACR Convergence, held in Philadelphia, November 10-14, 2022.“CAN10 continues to demonstrate promising effects in preclinical models of systemic sclerosis and the new data